We are live on ! Find out more
RCUS icon

Arcus Biosciences

92 hedge funds and large institutions have $375M invested in Arcus Biosciences in 2020 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 25 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

23% more funds holding

Funds holding: 75 → 92 (+17)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0.38% less ownership

Funds ownership: 59.1% → 58.72% (-0.38%)

3% less capital inflows, than outflows

Capital inflows: $61.7M | Capital outflows: $63.7M

4% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 26

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $8K

Holders
92
Holders Change
+17
Holders Change %
+22.67%
% of All Funds
2.02%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
25
Increased
25
Reduced
26
Closed
8
Calls
–
Puts
$8​K
Net Calls
-⁠$8​K
Net Calls Change
-⁠$21​K

RCUS Hedge Fund Activity: Q1 2020 in Review

92 of the 4,552 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2020, worth a combined $375M — up 37% from $274M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RCUS positions and 8 closed out — a net gain of 17 holders — while 25 added to existing stakes and 26 trimmed.

The largest buyer was Boxer Capital Management, adding an estimated $17.6M. The largest seller was BVF Inc, cutting an estimated $44M.

  • 92 institutional investors held Arcus Biosciences (RCUS) as of Q1 2020, up from 75 in Q4 2019.
  • Funds reported $375M of Arcus Biosciences stock for Q1 2020, up 37% quarter-over-quarter.
  • 25 funds opened new Arcus Biosciences positions in Q1 2020 and 8 closed out, a net change of +17 holders.
  • The largest Arcus Biosciences buyer in Q1 2020 was Boxer Capital Management, an estimated $17.6M added.
  • The largest Arcus Biosciences seller in Q1 2020 was BVF Inc, an estimated $44M sold.

Based on aggregated 13F filings for Q1 2020.